Jan Turner
About Jan Turner
Jan Turner is a Product Manager at Axol Bioscience Ltd. in Cambridge, England, specializing in iPSCs for patient stratification and cardiac models, with a strong background in genetic toxicology and product management.
Work at Axol Bioscience
Jan Turner has been serving as a Product Manager at Axol Bioscience Ltd. since 2022. Based in Cambridge, England, she focuses on the development and management of products related to induced pluripotent stem cells (iPSCs). Her role involves engaging in discussions about the application of iPSCs for patient stratification, which is crucial for personalized medicine. Turner has also participated in webinars that explore building cardiac models using iPSCs, contributing to the advancement of research in this area.
Education and Expertise
Jan Turner holds a PhD in Genetic Toxicology from Swansea University, where she also completed her Post Doctoral Research from 1990 to 1993. Additionally, she earned a BSc Hons in Biochemistry and Pharmacology from the University of Leeds. Her educational background provides a strong foundation for her expertise in product management within the biotechnology sector, particularly concerning genetic toxicology and stem cell technologies.
Background in Product Management
Jan Turner has extensive experience in product management, having worked in various roles across the biotechnology and healthcare sectors. She served as a Global Product Manager at GE Healthcare from 2003 to 2015, where she managed product lines related to healthcare technologies. Following this, she worked as a Product Management Operations Leader for Cell Therapy Technologies at GE Healthcare from 2015 to 2017. Turner also held the position of Senior Product Manager at BBI Solutions from 2017 to 2018 and was the Director at Safer Medicines Trust from 2019 to 2022.
Engagement in Webinars
Jan Turner has actively participated in various webinars that address significant challenges in the field of biomedical research. She presented a webinar focused on tackling challenges related to Alzheimer's disease and has engaged in discussions concerning neuroinflammation and compound screening. These webinars reflect her commitment to sharing knowledge and advancing understanding in critical areas of research.